Molecules, Vol. 25, Pages 2431: Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria
Molecules, Vol. 25, Pages 2431: Synergistic Activity of Nitroimidazole-Oxazolidinone Conjugates against Anaerobic Bacteria
Molecules doi: 10.3390/molecules25102431
Authors:
Zhijun Zhuang
Dawei Wan
Jun Ding
Shijie He
Qian Zhang
Xiaomei Wang
Ying Yuan
Yu Lu
Charles Z. Ding
Anthony Simon Lynch
Anna M. Upton
Christopher B. Cooper
William A. Denny
Zhenkun Ma
The introductions of the bicyclic 4-nitroimidazole and the oxazolidinone classes of antimicrobial agents represented the most significant advancements in the infectious disease area during the past two decades. Pretomanid, a bicyclic 4-nitroimidazole, and linezolid, an oxazolidinone, are also part of a combination regimen approved recently by the US Food and Drug Administration for the treatment of pulmonary, extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) Mycobacterium tuberculosis (TB). To identify new antimicrobial agents with reduced propensity for the development of resistance, a series of dual-acting nitroimidazole-oxazolidinone conjugates were designed, synthesized and evaluated for their antimicrobial activity. Compounds in this conjugate series have shown synergistic activity against a panel of anaerobic bacteria, including those responsible for serious bacterial infections.
Source: Molecules - Category: Chemistry Authors: Zhijun Zhuang Dawei Wan Jun Ding Shijie He Qian Zhang Xiaomei Wang Ying Yuan Yu Lu Charles Z. Ding Anthony Simon Lynch Anna M. Upton Christopher B. Cooper William A. Denny Zhenkun Ma Tags: Article Source Type: research
More News: Chemistry | Food and Drug Administration (FDA) | Infectious Diseases | Linezolid | Multidrug Resistance | Tuberculosis | Zyvox